https://world-heart-federation.org/news/deaths-from-cardiovascular-disease-surged-60-globally-over-the-last-30-years-report/ (accessed on 29th April 2024).

Saunders, H., Harris, D. & Chirilă, R. M. Pharmacogenomics: introduction and use in clinical practice. Rom. J. Intern. Med. 58, 69–74 (2020).

PubMed  Google Scholar 

Castrichini, M., Luzum, J. A. & Pereira, N. Pharmacogenetics of antiplatelet therapy. Annu. Rev. Pharmacol. Toxicol. 63, 211–229 (2023).

CAS  PubMed  Google Scholar 

Galli, M. et al. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev. Clin. Pharmacol. 14, 963–978 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Falco, L. et al. Antioxidant properties of oral antithrombotic therapies in atherosclerotic disease and atrial fibrillation. Antioxidants 12, 1185 (2023).

CAS  PubMed  PubMed Central  Google Scholar 

Akkaif, M. A. et al. The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD). Molecules 26, 1987 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Saiz-Rodríguez, M. et al. Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention. Clin. Ther. 41, 1199–1212.e1192 (2019).

PubMed  Google Scholar 

Lopez, J. et al. Role of genetic polymorphisms in clopidogrel response variability: a systematic review. Open Heart 10, e002436 (2023).

PubMed  PubMed Central  Google Scholar 

Lee, C. R. et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin. Pharmacol. Ther.112, 959–967 (2022).

CAS  PubMed  Google Scholar 

Ellithi, M., Baye, J. & Wilke, R. A. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics 21, 889–897 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Su, Q. et al. Association of CYP2C19 polymorphism with clopidogrel resistance in patients with acute coronary syndrome in China. Med. Sci. Monit.25, 7138 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Zhuo, Z. -l. et al. Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. Anatol. J. Cardiol. 19, 123 (2018).

CAS  PubMed  PubMed Central  Google Scholar 

Peng, W., Shi, X., Xu, X. & Lin, Y. Both CYP2C19 and PON1 Q192R genotypes influence platelet response to clopidogrel by thrombelastography in patients with acute coronary syndrome. Cardiovasc. Ther. 2019, 3470145 (2019).

PubMed  PubMed Central  Google Scholar 

Liu, G., Yang, S. & Chen, S. The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention. Medicine 99, e19143 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Li, Y.-J. et al. Association between CYP2C19 polymorphisms and clinical outcomes in patients undergoing stent procedure for cerebral artery stenosis. Sci. Rep. 11, 5974 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Biswas, M., Sukasem, C., Khatun Kali, M. S. & Ibrahim, B. Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Pharmacogenomics 23, 207–220 (2022).

CAS  PubMed  Google Scholar 

Xi, Z. et al. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: a systematic review and meta-analysis. Platelets 30, 229–240 (2019).

CAS  PubMed  Google Scholar 

Sibbing, D. et al. Cytochrome 2C19* 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512–518 (2010).

CAS  PubMed  Google Scholar 

Lewis, J. P. et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur. Heart J. Cardiovasc. Pharmacother. 6, 203–210 (2020).

PubMed  Google Scholar 

Lee, C. R. et al. Impact of the CYP2C19* 17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. Clin. Pharmacol. Ther. 109, 705–715 (2021).

CAS  PubMed  Google Scholar 

Dehbozorgi, M. et al. Prevalence of the CYP2C19* 2 (681 G> A),* 3 (636 G> A) and* 17 (‑806 C> T) alleles among an Iranian population of different ethnicities. Mol. Med. Rep. 17, 4195–4202 (2018).

CAS  PubMed  PubMed Central  Google Scholar 

Yamada, H. et al. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur. J. Clin. Pharmacol. 54, 479–481 (1998).

CAS  PubMed  Google Scholar 

Brockmöller, J. J., Rost, K., Gross, D., Schenkel, A. & Roots, I. Phenotyping of CYP2C19 with enantiospecific HPLCquantification of R-and S-mephenytoin and comparison with the intron4/exon5 G→ A-splice site mutation. Pharmacogenetics 5, 80–88 (1995).

PubMed  Google Scholar 

Persson, I., Aklillu, E., Rodrigues, F., Bertilsson, L. & Ingelman-Sundberg, M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6, 521–526 (1996).

CAS  PubMed  Google Scholar 

Dandara, C. et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east-and southern African populations including psychiatric patients. Eur. J. Clin. Pharmacol. 57, 11–17 (2001).

CAS  PubMed  Google Scholar 

Goldstein, J. A. et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59–64 (1997).

CAS  PubMed  Google Scholar 

Sistonen, J. et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 19, 170–179 (2009).

CAS  PubMed  Google Scholar 

Jurima-Romet, M. et al. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics 6, 329–339 (1996).

CAS  PubMed  Google Scholar 

Bathum, L., Andersen-Ranberg, K., Boldsen, J., Brøsen, K. & Jeune, B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevity: role of CYP2D6 and CYP2C19 in longevity. Eur. J. Clin. Pharmacol. 54, 427–430 (1998).

CAS  PubMed  Google Scholar 

Herrlin, K. et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther. 64, 391–401 (1998).

CAS  PubMed  Google Scholar 

Pedersen, R. S. et al. Linkage disequilibrium between the CYP2C19* 17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur. J. Clin. Pharmacol. 66, 1199–1205 (2010).

PubMed  Google Scholar 

Hamdy, S. I. et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol. 53, 596–603 (2002).

CAS  PubMed  PubMed Central  Google Scholar 

Hsu, H.-L., Woad, K. J., Woodfield, D. G. & Helsby, N. A. A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea. Hum. Genomics 3, 1–7 (2008).

Google Scholar 

Rudberg, I., Mohebi, B., Hermann, M., Refsum, H. & Molden, E. Impact of the ultrarapid CYP2C19* 17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83, 322–327 (2008).

CAS  PubMed  Google Scholar 

Kearns, G. L., Leeder, J. S. & Gaedigk, A. Impact of the CYP2C19* 17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab. Dispos. 38, 894–897 (2010).

CAS  PubMed  PubMed Central  Google Scholar 

Sim, S. C. et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103–113 (2006).

CAS  PubMed  Google Scholar 

Kim, K. A., Song, W. K., Kim, K. R. & Park, J. Y. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19* 2, CYP2C19* 3, and CYP2C19* 17 alleles. J. Clin. Pharm. Ther. 35, 697–703 (2010).

PubMed  Google Scholar 

Sugimoto, K., Uno, T., Yamazaki, H. & Tateishi, T. Limited frequency of the CYP2C19* 17 allele and its minor role in a Japanese population. Br. J. Clin. Pharmacol. 65, 437–439 (2008).